GSK-3β Directly Phosphorylates and Activates MARK2/PAR-1

• Published in: The Journal of biological chemistry 2005-12, Vol.280 (52), p.42715-42722
• Main Authors: Kosuga, Shinichi, Tashiro, Etsu, Kajioka, Toshifumi, Ueki, Mayumi, Shimizu, Yoshifumi, Imoto, Masaya
• Format: Article
• Language: English
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M507941200

In Alzheimer disease (AD), the microtubule-associated protein tau is found hyperphosphorylated in paired helical filaments. Among many phosphorylated sites in tau, Ser-262 is the major site for abnormal phosphorylation of tau in AD brain. The kinase known to phosphorylate this particular site is MARK2, whose activation mechanism is yet to be studied. Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3β (GSK-3β), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3β in MARK2 activation. In vitro kinase reaction revealed that recombinant GSK-3β indeed phosphorylates MARK2, whereas it failed to phosphorylate Ser-262 of tau. Our further findings led us to conclude that GSK-3β phosphorylates MARK2 on Ser-212, one of the two reported phosphorylation sites (Thr-208 and Ser-212) found in the activation loop of MARK2. Down-regulation of either GSK-3β or MARK2 by small interfering RNAs suppressed the level of phosphorylation on Ser-262. These results, respectively, indicated that GSK-3β is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3β-MARK2 pathway. These findings are of interest in the context of the pathogenesis of AD.